NIA Alzheimer's Drug-Development Program
Funds collaborative research alliances that accelerate Alzheimer's drug development in the United States.
The NIA Alzheimer's Drug-Development Program (ADDP), funded under FOAs PAR-24-223 and PAR-25-297, supports drug discovery and development studies targeting Alzheimer's disease through U01 cooperative agreements. As a cooperative agreement, NIA scientific staff play an active and substantive role in project direction throughout the award period — reviewing milestones, participating in scientific de…
Drug discovery and development targeting Alzheimer's disease, including drug repositioning, combination therapy, and translational bioinformatics approaches funded as cooperative agreements.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see the timeline
Guides for this application
All guides →NIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
Submit & reportSAM.gov Registration and UEI Guide for Federal Grant Applicants
Learn how SAM.gov registration, UEI numbers, Grants.gov accounts, organization profiles, workspace roles, and renewal timing fit together.
More from NIA
All grants from this funder →2026 NIA Mentorship Prize Competition
🇺🇸NIA · United States
Pays $100,000 to each of up to six faculty mentors recognized for outstanding aging-research mentorship.
NIA SBIR Phase I
🇺🇸NIA · United States
Supports small businesses developing aging and memory technologies at the feasibility stage.
NIA SBIR Phase II
🇺🇸NIA · United States
Funds small businesses advancing aging biology and Alzheimer's disease technologies through full development execution.
NIA STTR Phase I
🇺🇸NIA · United States
Supports small businesses partnering with universities on aging innovation at feasibility stage.
NIA R01: Drug Repositioning and Combination Therapy for Alzheimer's Disease
NIA · United States
Funds researchers combining computational and experimental approaches to test repositioned drugs for Alzheimer's disease treatment through NIH R01 grants.
NIA Start-Up Challenge
🇺🇸NIA · United States
Funds US entrepreneurs and small businesses developing healthy-aging technologies through NIA's Start-Up Challenge cash prizes and accelerator.
Similar grants
Browse the directory →
NIH Common Fund Venture Program — Open Funding (Seed)
🇺🇸NIH Common Fund · United States
Supports high-potential short- to medium-range initiatives that can seed major breakthroughs.
ARPA-H Program ISOs (topic-specific)
🇺🇸ARPA-H · United States
Funds United States health initiatives through topic-focused pathways across multiple mission areas and agencies.
First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders
🇺🇸NIH · United States
Funds the first human trials of a novel-mechanism psychiatric drug or a novel neuromodulatory device, with milestones gating each step.
Defense Health Agency SBIR Phase I
🇺🇸DHA · United States
Funds United States defense medical innovators at feasibility stage for life-changing military health technologies.
Defense Health Agency SBIR Phase II
🇺🇸DHA · United States
Supports United States defense health teams maturing validated medical technologies toward practical military use.
ARPA-H SBIR/STTR
🇺🇸ARPA-H · United States
Funds United States small businesses bridging health and neuroscience technologies from feasibility into advanced development.